Logo do repositório
 
Publicação

The effects of benralizumab on lung volumes and airway resistance in severe eosinophilic asthma: a real-world study

2024-01Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorGerardo, António Madeira
dc.contributor.authorAlves, Carolina da Silva
dc.contributor.authorGomes, Margarida
dc.contributor.authorPardal, Cecília
dc.contributor.authorSokolova, Anna
dc.contributor.authorLiberato, Hedi
dc.contributor.authorMendes, Ana
dc.contributor.authorTonin, Fernanda
dc.contributor.authorDuarte-Ramos, Filipa
dc.contributor.authorLopes, Carlos
dc.date.accessioned2024-03-01T12:03:26Z
dc.date.available2024-03-01T12:03:26Z
dc.date.issued2024-01
dc.description.abstractIntroduction: Add-on biological monoclonal antibodies such as benralizumab (anti-IL-5Ra) are recommended by international guidelines to reduce exacerbations in severe eosinophilic asthma (SEA). However, few studies have assessed the impact of these therapies on lung function-related outcomes. Our goal was to evaluate the effectiveness of benralizumab on lung function, including lung volumes and airway resistance, in SEA patients in Portugal. Methods: This was a real-world, observational, prospective, multicentric study including adult patients diagnosed with SEA (January-June 2023). Spirometry and plethysmography were performed at baseline (T0) and after six months of treatment (T6) with benralizumab to assess: total lung capacity (TLC), residual volume (RV), forced expiratory volume in one second (FEV1), forced vital capacity (FVC), mean forced expiratory flow between 25% and 75% of FVC (mFEF-25/75), intrathoracic gas volume (ITGV), and respiratory airway resistance (Raw). Descriptive statistics (with categorical variables described as frequencies and continuous values as mean and standard deviation (SD)) and paired t-test and Cohen's d effect size were calculated (analyses performed in StataCorp v.15.1; StataCorp LLC, TX, USA). Results: Overall, 30 SEA patients were evaluated, mostly women (n=18, 60.0%), with atopy (n=22, 73.3%), a mean age of 58.4 years (SD 11.7), and assisted by pulmonology (n=19, 63.3%) or immunology-allergology (n=11, 36.7%) services. Mean eosinophilia at baseline was 1103.57 cells/mcL (SD 604.88; minimum-maximum 460-2400); after the use of benralizumab, the count dropped to zero. After six months of treatment, a significant increase (p<0.0001) in FVC (15.3%), FEV1 (22.6%), and mFEF-25/75 (17.7%) were observed from baseline (Cohen's d between 0.78 and 1.11). ITGV, RV, RV/TLC, and Raw significantly decreased (p<0.0001) during the study period (-17.3%, -29.7%, -8.9%, and -100.6%, respectively) (Cohen's d between -0.79 and -1.06). No differences in TLC were obtained (p=0.173). No differences between sexes were observed for any measure. Patients with more significant eosinophilia (>900 cells/mcL count; n=15) presented better responses in FEV1 (p=0.001) and mFEF-25/75 (p=0.007). Conclusions: A notable eosinophil depletion with add-on benralizumab led to significant improvements in SEA patients' respiratory function (static lung volumes and airway resistance) in real-world settings after six months. The significant deflating effect of benralizumab on patients' hyperinflated lungs led to enhanced expiratory flow (increased FEV1 and mFEF-25/75) and air trapping (decreased RV/TLC), suggesting this antibody improves bronchial obstruction, lung hyperinflation, and airway resistance. Further studies in a larger population are required to confirm these findings.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationGerardo AM, Alves CS, Gomes M, Pardal C, Sokolova A, Tonin FS, et al. The effects of benralizumab on lung volumes and airway resistance in severe eosinophilic asthma: a real-world study. Cureus. 2024;16(1):e52452.pt_PT
dc.identifier.doi10.7759/cureus.52452pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/17167
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherPubMed Centralpt_PT
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871543/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectBenralizumabpt_PT
dc.subjectAnti-il5pt_PT
dc.subjectRespiratory functionpt_PT
dc.subjectSevere eosinophilic asthmapt_PT
dc.subjectt2 inflammationpt_PT
dc.titleThe effects of benralizumab on lung volumes and airway resistance in severe eosinophilic asthma: a real-world studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPagee52452pt_PT
oaire.citation.titleCureuspt_PT
oaire.citation.volume16pt_PT
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
The effects of benralizumab on lung volumes and airway resistance in severe eosinophilic asthma_a real-world study.pdf
Tamanho:
221.36 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ESTeSL - Artigos